

# Efsevia Vakiani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7289411/publications.pdf>

Version: 2024-02-01

110  
papers

11,806  
citations

53751

45  
h-index

28275

105  
g-index

111  
all docs

111  
docs citations

111  
times ranked

19656  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival. <i>Annals of Surgery</i> , 2022, 275, 371-381.	2.1	4
2	Immunofluorescence Assay of Ablated Colorectal Liver Metastases: The Frozen Section of Image-Guided Tumor Ablation?. <i>Journal of Vascular and Interventional Radiology</i> , 2022, 33, 308-315.e1.	0.2	6
3	Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases. <i>Cancers</i> , 2022, 14, 693.	1.7	14
4	Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer. <i>Oncologist</i> , 2022, 27, 380-388.	1.9	12
5	Pathological Evaluation of Rectal Cancer Specimens Using Micro-Computed Tomography. <i>Diagnostics</i> , 2022, 12, 984.	1.3	2
6	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. <i>JCO Precision Oncology</i> , 2022, , .	1.5	1
7	Detecting mismatch repair deficiency in solid neoplasms: immunohistochemistry, microsatellite instability, or both?. <i>Modern Pathology</i> , 2022, 35, 1515-1528.	2.9	13
8	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 817-825.	0.7	8
9	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	3.2	51
10	OncoTree: A Cancer Classification System for Precision Oncology. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 221-230.	1.0	51
11	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	0.8	34
12	Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection. <i>Clinical Cancer Research</i> , 2021, 27, 4101-4108.	3.2	24
13	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. <i>Nature Communications</i> , 2021, 12, 3770.	5.8	68
14	Genome-Derived Classification Signature for Ampullary Adenocarcinoma to Improve Clinical Cancer Care. <i>Clinical Cancer Research</i> , 2021, 27, 5891-5899.	3.2	9
15	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1683-1692.	3.0	66
16	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	3.6	73
17	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	2.8	16
18	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. <i>JAMA Oncology</i> , 2020, 6, 84.	3.4	66

#	ARTICLE	IF	CITATIONS
19	Discordant DNA mismatch repair protein status between synchronous or metachronous gastrointestinal carcinomas: frequency, patterns, and molecular etiologies. <i>Familial Cancer</i> , 2020, 20, 201-213.	0.9	8
20	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	2.1	3
21	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1129-1139.	7.7	245
22	Cdc42 Mediates Cancer Cell Chemotaxis in Perineural Invasion. <i>Molecular Cancer Research</i> , 2020, 18, 913-925.	1.5	19
23	Coaltered <i>Ras/B-raf</i> and <i>TP53</i> Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1077-1085.	3.2	62
24	Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4602-4602.	0.8	0
25	Somatic HNF1A mutations in the malignant transformation of hepatocellular adenomas: a retrospective analysis of data from MSK-IMPACT and TCGA. <i>Human Pathology</i> , 2019, 83, 1-6.	1.1	14
26	Contemporary Validation of a Nomogram Predicting Colon Cancer Recurrence, Revealing All-Stage Improved Outcomes. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz015.	1.4	16
27	Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. <i>Human Pathology</i> , 2019, 91, 19-25.	1.1	12
28	Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade. <i>Modern Pathology</i> , 2019, 32, 1551-1562.	2.9	12
29	Fluorescent Tissue Assessment of Colorectal Cancer Liver Metastases Ablation Zone: A Potential Real-Time Biomarker of Complete Tumor Ablation. <i>Annals of Surgical Oncology</i> , 2019, 26, 1833-1840.	0.7	18
30	Cellular localization of PD-L1 expression in mismatch-repair-deficient and proficient colorectal carcinomas. <i>Modern Pathology</i> , 2019, 32, 110-121.	2.9	28
31	<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer. <i>Cancer Discovery</i> , 2019, 9, 199-209.	7.7	115
32	Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy. <i>JAMA Oncology</i> , 2019, 5, e185896.	3.4	347
33	Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3585-3585.	0.8	1
34	Poorly Differentiated Clusters Predict Colon Cancer Recurrence. <i>American Journal of Surgical Pathology</i> , 2018, 42, 705-714.	2.1	61
35	Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer. <i>Oncolmmunology</i> , 2018, 7, e1435227.	2.1	16
36	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 33, 125-136.e3.	7.7	589

#	ARTICLE	IF	CITATIONS
37	Immediate Postablation <sup>18</sup> F-FDG Injection and Corresponding SUV Are Surrogate Biomarkers of Local Tumor Progression After Thermal Ablation of Colorectal Carcinoma Liver Metastases. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1360-1365.	2.8	33
38	Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. <i>JAMA Oncology</i> , 2018, 4, e180071.	3.4	404
39	Logarithmic expansion of LGR5 + cells in human colorectal cancer. <i>Cellular Signalling</i> , 2018, 42, 97-105.	1.7	35
40	Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations. <i>Familial Cancer</i> , 2018, 17, 225-228.	0.9	17
41	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. <i>Cancer Discovery</i> , 2018, 8, 49-58.	7.7	275
42	Intrahepatic Cholangiocarcinomas Have Histologically and Immunophenotypically Distinct Small and Large Duct Patterns. <i>American Journal of Surgical Pathology</i> , 2018, 42, 1334-1345.	2.1	45
43	Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 3520-3520.	0.8	3
44	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. <i>Familial Cancer</i> , 2017, 16, 525-529.	0.9	18
45	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	15.2	2,473
46	A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions. <i>American Journal of Surgical Pathology</i> , 2017, 41, 980-988.	2.1	77
47	Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. <i>Human Pathology</i> , 2017, 62, 74-82.	1.1	17
48	Morphological characterization of colorectal cancers in The Cancer Genome Atlas reveals distinct morphologyâ€“molecular associations: clinical and biological implications. <i>Modern Pathology</i> , 2017, 30, 599-609.	2.9	74
49	Molecular Testing of Colorectal Cancer in the Modern Era. <i>Surgical Pathology Clinics</i> , 2017, 10, 1009-1020.	0.7	4
50	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. <i>Cancer Research</i> , 2017, 77, 6513-6523.	0.4	58
51	Inflammatory Monocytes Promote Perineural Invasion via CCL2-Mediated Recruitment and Cathepsin B Expression. <i>Cancer Research</i> , 2017, 77, 6400-6414.	0.4	73
52	Clinical and genetic determinants of ovarian metastases from colorectal cancer. <i>Cancer</i> , 2017, 123, 1134-1143.	2.0	43
53	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. <i>Cancer</i> , 2017, 123, 568-575.	2.0	39
54	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. <i>Oncotarget</i> , 2017, 8, 66117-66127.	0.8	80

#	ARTICLE	IF	CITATIONS
55	SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate.. Journal of Clinical Oncology, 2017, 35, 587-587.	0.8	5
56	Total neoadjuvant therapy for locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 662-662.	0.8	3
57	Evolution in multimodality management of locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 684-684.	0.8	1
58	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	0.8	10
59	Poorly differentiated clusters as a prognostic marker at the invasive front of colon cancer.. Journal of Clinical Oncology, 2017, 35, 621-621.	0.8	1
60	Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival.. Journal of Clinical Oncology, 2017, 35, 3534-3534.	0.8	1
61	Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients.. Journal of Clinical Oncology, 2017, 35, 3581-3581.	0.8	0
62	Total neoadjuvant chemotherapy to facilitate delivery and tolerance of systemic chemotherapy and response in locally advanced rectal cancer.. Journal of Clinical Oncology, 2017, 35, 3519-3519.	0.8	4
63	Recurrent, truncating <i>SOX9</i> mutations are associated with <i>SOX9</i> overexpression, <i>KRAS</i> mutation, and <i>TP53</i> wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	0.8	26
64	Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1098-1104.	1.1	9
65	ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance. Human Pathology, 2016, 53, 97-104.	1.1	18
66	Distance to the anal verge is associated with pathologic complete response to neoadjuvant therapy in locally advanced rectal cancer. Journal of Surgical Oncology, 2016, 114, 637-641.	0.8	35
67	Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Modern Pathology, 2016, 29, 1433-1442.	2.9	144
68	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	1.5	46
69	Schwann cells induce cancer cell dispersion and invasion. Journal of Clinical Investigation, 2016, 126, 1538-1554.	3.9	176
70	Immunohistochemical Detection of the BRAF V600E Mutant Protein in Colorectal Neoplasms. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 438-443.	0.6	17
71	HER2 Testing in Gastric and Gastroesophageal Adenocarcinomas. Advances in Anatomic Pathology, 2015, 22, 194-201.	2.4	23
72	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer, 2015, 121, 1195-1203.	2.0	146

#	ARTICLE	IF	CITATIONS
73	Pilot Trial of Combined BRAF and EGFR Inhibition in <i>BRAF</i> -Mutant Metastatic Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 1313-1320.	3.2	240
74	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2). <i>Modern Pathology</i> , 2015, 28, 1123-1129.	2.9	51
75	Mismatch repair deficient-crypts in non-neoplastic colonic mucosa in Lynch syndrome: insights from an illustrative case. <i>Familial Cancer</i> , 2015, 14, 61-68.	0.9	27
76	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. <i>Molecular Cancer Research</i> , 2015, 13, 1003-1008.	1.5	20
77	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. <i>PLoS ONE</i> , 2015, 10, e0134731.	1.1	38
78	Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 668-75.	0.6	22
79	<i>KRAS</i> mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. <i>Cancer</i> , 2014, 120, 3965-3971.	2.0	127
80	Immunohistochemical detection of ARID1A in colorectal carcinoma: loss of staining is associated with sporadic microsatellite unstable tumors with medullary histology and high TNM stage. <i>Human Pathology</i> , 2014, 45, 2430-2436.	1.1	41
81	Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2014, 38, 437-447.	2.1	216
82	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 207-212.	1.0	37
83	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2014, 120, 2316-2324.	2.0	170
84	GFR $\alpha$ released by nerves enhances cancer cell perineural invasion through GDNF-RET signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2008-17.	3.3	102
85	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. <i>Cancer Discovery</i> , 2013, 3, 294-307.	7.7	53
86	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. <i>Nature Genetics</i> , 2013, 45, 253-261.	9.4	324
87	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunorepression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. <i>Modern Pathology</i> , 2013, 26, 131-138.	2.9	82
88	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. <i>Journal of Clinical Oncology</i> , 2012, 30, 2956-2962.	0.8	254
89	The 2011 Fred Waldorf Stewart Award Recipient. <i>American Journal of Surgical Pathology</i> , 2012, 36, 479-480.	2.1	0
90	Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 173-184.	2.1	468

#	ARTICLE	IF	CITATIONS
91	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2012, 11, 101-111.	1.0	67
92	Radiation Impairs Perineural Invasion by Modulating the Nerve Microenvironment. <i>PLoS ONE</i> , 2012, 7, e39925.	1.1	48
93	A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK0646 in patients with metastatic, well-differentiated neuroendocrine tumors. <i>Cancer</i> , 2012, 118, 4795-4800.	2.0	59
94	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. <i>Nature</i> , 2012, 486, 532-536.	13.7	1,605
95	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 447-454.	2.1	82
96	KRAS and BRAF: drug targets and predictive biomarkers. <i>Journal of Pathology</i> , 2011, 223, 220-230.	2.1	133
97	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4240-4246.	0.8	129
98	Collagenous sprue is not always associated with dismal outcomes: a clinicopathological study of 19 patients. <i>Modern Pathology</i> , 2010, 23, 12-26.	2.9	89
99	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. <i>Cancer Research</i> , 2010, 70, 5901-5911.	0.4	245
100	Pathologic Features and Biologic Importance of Colorectal Serrated Polyps. <i>Advances in Anatomic Pathology</i> , 2009, 16, 79-91.	2.4	40
101	Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1639-1645.	2.1	155
102	Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2008, 12, 91-100.	0.9	77
103	Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. <i>Hematological Oncology</i> , 2008, 26, 199-211.	0.8	89
104	The Spectrum of B-Cell Non-Hodgkin Lymphomas With Dual <i>IgH</i> - <i>BCL2</i> and <i>BCL6</i> Translocations. <i>American Journal of Clinical Pathology</i> , 2008, 130, 193-201.	0.4	17
105	Acinar Cell Carcinoma of the Pancreas Metastatic to the Ovary. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1540-1545.	2.1	27
106	Hepatitis C-Associated Granulomas After Liver Transplantation. <i>American Journal of Clinical Pathology</i> , 2007, 127, 128-134.	0.4	35
107	Gene Expression Analysis of B-Cell Post Transplant Lymphoproliferative Disorders Provides Insights into Disease Biology. <i>Blood</i> , 2007, 110, 3172-3172.	0.6	0
108	CD117 expression in diffuse large B-cell lymphomas: Fact or fiction?. <i>Pathology International</i> , 2005, 55, 716-723.	0.6	13

#	ARTICLE	IF	CITATIONS
109	T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: A case report and review of the literature. American Journal of Hematology, 2005, 80, 216-222.	2.0	6
110	Successful Bilateral Lung Transplantation for Pulmonary Fibrosis Associated With the Hermansky-Pudlak Syndrome. Journal of Heart and Lung Transplantation, 2005, 24, 1697-1699.	0.3	52